Ken Fisher
NWBO

Ken Fisher’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Ken Fisher’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,500
Closed -$21K – 985
2021
Q2 		$21K Buy
+14,500
New +$21K ﹤0.01% 912

Other funds holding NWBO

MSAM
Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return
GWI
Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return
AIP
Almanack Investment Partners Wayne, Pennsylvania $785M AUM 34.37% 1-Year Est. Return
LDB
Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Ken Fisher's NWBO Position: Q3 2021 in Review

Ken Fisher sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2021, closing a stake of 14,500 shares — an estimated $21K sold.

Ken Fisher first reported a position in NWBO in Q2 2021 and held it in 1 quarter. The position peaked at $21K in Q2 2021. 10 funds tracked by Wall St. Rank hold NWBO as of Q3 2021.

  • Ken Fisher reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2021 after selling out during the quarter.
  • Ken Fisher sold 14,500 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2021, an estimated $21K.
  • Ken Fisher first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2021 and held it in 1 quarter.
  • Ken Fisher's Northwest Biotherapeutics, Inc. Common stock position peaked at $21K in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2021.

Based on Fisher Asset Management's 13F filing for Q3 2021, filed 26 Oct 2021.